Viralytics Limited (VLA) is pleased to announce the granting of a notice of allowance by the United States Patent and Trademark Office (USPTO) of a patent around CAVATAKTM, Viralytics’ Phase II cancer drug based on Coxsackievirus A21. The USPTO has advised Viralytics that the patent will grant on August 7, 2012 being identified as US Patent No. 8,236,298. Specifically, the claims in the notice of allowance cover the use of Picornaviruses (a large family of viruses including Coxsackievirus A21) to destroy cancerous blood cells in stem cell grafts prior to transplantation.
Dr Darren Shafren, Viralytics Chief Scientific Officer said “the use of Picornaviruses, including CAVATAKTM to target and destroy cancerous cells in stem cell transplants used in treatment of blood cancer is a new and exciting application of Viralytics’ oncolytic viruses. Our current clinical strategy for CAVATAKTM is to focus on both intratumoural (injecting directly into the tumour) and intravenous (via the bloodstream) routes of delivery.
Viralytics is listed on the Australian Stock Exchange (VLA), Viralytics ADR trades under VRACY on the OTC market in the USA. Viralytics’ principal asset is the intellectual property relating to CAVATAKTM, an Oncolytic Virus technology.